AVS Bio Acquires Biorbyt Ltd. to Expand Research Reagents

AVS Bio, a key player in the bioprocessing and biologics supply chain backed by Arlington Capital Partners, has significantly expanded its research product portfolio through the acquisition of Biorbyt Ltd. This strategic move enhances AVS Bio's capabilities in providing critical inputs for the life sciences sector, aiming to solidify its position as a comprehensive biomaterials provider.

The integration of Biorbyt, a UK-based specialist in bio-reagents, antibodies, and proteins, introduces over one million distinct research products to AVS Bio's existing offerings. This broadens the company's reach into pharmaceutical, biotechnology, and academic research markets globally. Biorbyt's established e-commerce platform is expected to accelerate AVS Bio's digital commercialization efforts and improve customer access to a wider array of research tools.

Jac Price, CEO of AVS Bio, highlighted the acquisition's importance in addressing the increasing complexity of disease treatment and prevention. "Biorbyt's extensive catalog and advanced digital infrastructure are pivotal in our strategy to become a leading, diversified global biomaterials supplier," Price stated. "This partnership will enable us to serve a larger customer base across more territories than ever before."

Arlington Capital Partners, which focuses on building scaled life sciences platforms, views this acquisition as a crucial step in its long-term vision for AVS Bio. Malcolm Little, a Partner at Arlington, commented, "The addition of Biorbyt materially expands AVS Bio's product breadth and introduces sophisticated digital commerce capabilities. This aligns perfectly with our objective to create a differentiated platform at the forefront of life science innovation." The private equity firm has a history of investing in companies that enhance healthcare infrastructure, including recent investments in Afton Scientific and Grand River Aseptic Manufacturing.

Biorbyt, founded in 2011, has cultivated a substantial catalog encompassing primary and secondary antibodies, recombinant proteins, ELISA kits, and molecular biology reagents. Its sophisticated online sales channel has served a worldwide clientele. Following the transaction, Biorbyt will continue its operations under its current leadership, integrating its product lines and digital expertise into the AVS Bio platform to offer a unified procurement experience for researchers.

The combined entity is positioned to capitalize on the growing demand for specialized biological materials, driven by advancements in personalized medicine and biopharmaceutical development. The global life science reagents market is projected to experience steady growth, fueled by increased R&D spending and the expanding pipeline of biologic drugs. AVS Bio's expanded offering, now including Biorbyt's extensive catalog, provides a significant competitive advantage in this dynamic market.

Dr. Tillmann Ziegert and Qun Yang, Co-Founders of Biorbyt, expressed enthusiasm for joining AVS Bio. "Our combined product portfolios, coupled with our advanced e-commerce capabilities, create a potent engine for supporting researchers worldwide," they noted. "We anticipate delivering an even more comprehensive suite of high-quality biomaterials to our shared global customer base."